日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade

MCL1 抑制靶向髓系抑制细胞,促进抗肿瘤免疫并增强免疫检查点阻断的疗效

Nabanita Mukherjee, Elizabeth Katsnelson, Tonya M Brunetti, Kylie Michel, Kasey L Couts, Karoline A Lambert, William A Robinson, Martin D McCarter, David A Norris, Richard P Tobin, Yiqun G Shellman

Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics

葡萄膜黑色素瘤和皮肤黑色素瘤中 BCL2 家族成员的表达差异导致对 BH3 模拟物的敏感性不同

Nabanita Mukherjee, Chiara R Dart, Carol M Amato, Adam Honig-Frand, James R Lambert, Karoline A Lambert, William A Robinson, Richard P Tobin, Martin D McCarter, Kasey L Couts, Mayumi Fujita, David A Norris, Yiqun G Shellman

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine

治疗黑色素瘤的新方案:MCL1 抑制剂和阿扎胞苷

Chiara R Dart, Nabanita Mukherjee, Carol M Amato, Anabel Goulding, Morgan MacBeth, Robert Van Gulick, Kasey L Couts, James R Lambert, David A Norris, William A Robinson, Yiqun G Shellman

Loss of prdm1a accelerates melanoma onset and progression

prdm1a 的缺失会加速黑色素瘤的发生和进展

Ritsuko Iwanaga, Brittany T Truong, Jessica Y Hsu, Karoline A Lambert, Rajesh Vyas, David Orlicky, Yiqun G Shellman, Aik-Choon Tan, Craig Ceol, Kristin Bruk Artinger

Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma

同时抑制 BCL2 和 MCL1 是晚期黑色素瘤患者的一种治疗选择

Nabanita Mukherjee, Carol M Amato, Jenette Skees, Kaleb J Todd, Karoline A Lambert, William A Robinson, Robert Van Gulick, Ryan M Weight, Chiara R Dart, Richard P Tobin, Martin D McCarter, Mayumi Fujita, David A Norris, Yiqun G Shellman

BH3 mimetics induce apoptosis independent of DRP-1 in melanoma

BH3 类似物诱导黑色素瘤细胞凋亡,且不依赖于 DRP-1

Nabanita Mukherjee, Andrew Strosnider, Bay Vagher, Karoline A Lambert, Sarah Slaven, William A Robinson, Carol M Amato, Kasey L Couts, Judson G T Bemis, Jacqueline A Turner, David A Norris, Yiqun G Shellman

ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms

表达EML4-ALK融合基因和替代ALK亚型的黑色素瘤对ALK抑制剂的反应

Kasey L Couts ,Judson Bemis ,Jacqueline A Turner ,Stacey M Bagby ,Danielle Murphy ,Jason Christiansen ,Jennifer D Hintzsche ,Anh Le ,Todd M Pitts ,Keith Wells ,Allison Applegate ,Carol Amato ,Pratik Multani ,Edna Chow-Maneval ,John J Tentler ,Yiqun G Shellman ,Matthew J Rioth ,Aik-Choon Tan ,Rene Gonzalez ,Theresa Medina ,Robert C Doebele ,William A Robinson

Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma

全外显子组测序在黏膜黑色素瘤中发现复发性SF3B1 R625突变以及NF1和KIT的共突变

Jennifer D Hintzsche ,Nicholas T Gorden, Carol M Amato, Jihye Kim, Kelsey E Wuensch, Steven E Robinson, Allison J Applegate, Kasey L Couts, Theresa M Medina, Keith R Wells, Joshua A Wisell, Martin D McCarter, Neil F Box, Yiqun G Shellman, Rene C Gonzalez, Karl D Lewis, John J Tentler, Aik Choon Tan, William A Robinson

Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells

单独使用 MCL-1 抑制剂来缩小黑色素瘤体积,并联合使用来杀死黑色素瘤起始细胞

Nabanita Mukherjee, Yan Lu, Adam Almeida, Karoline Lambert, Chung-Wai Shiau, Jung-Chen Su, Yuchun Luo, Mayumi Fujita, William A Robinson, Steven E Robinson, David A Norris, Yiqun G Shellman

Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments

结合 GSI 和 BCL-2 抑制剂来克服黑色素瘤对当前治疗的耐药性

Nabanita Mukherjee, Adam Almeida, Katie A Partyka, Yan Lu, Josianna V Schwan, Karoline Lambert, Madison Rogers, William A Robinson, Steven E Robinson, Allison J Applegate, Carol M Amato, Yuchun Luo, Mayumi Fujita, David A Norris, Yiqun G Shellman